Endometrial cancer trials in Italy

In Italy 61 Also abroad 395

61 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
Where
Bari, Bologna, Catania, Meldola, Milan, Modena, Naples, Perugia, Pisa, Rome, Treviso, Turin, Varese, Venice, Verona, Vicenza
Age
18 years and over
People
480 worldwide
Run by
BioNTech SE
See details and how to joinNCT06340568 · EU 2023-507525-42-00
Phase 3Taking people
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Where
Catania, Florence, Meldola, Milan, Naples, Pisa, Rome, Treviso, Turin
Age
18 years and over
People
1,123 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06952504 · EU 2024-519331-42-00
Phase 1Taking people
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Where
Milan
Age
18 years and over
People
575 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06400472 · EU 2024-511238-11-00
Phase 2Taking people
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Where
Milan, Reggio Emilia, Rome
Age
18 years and over
People
111 worldwide
Run by
Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00
No phaseNot yet taking people in Italy
Gut Microbiome in Patients With Lung and Melanoma Cancer and Intestinal Microbiota in Gynecologic Cancers
Where
Milan
Age
18 years and over
People
360
Run by
European Institute of Oncology
See details and how to joinNCT07815873
Phase 3Taking people
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
Where
Bologna, Catania, Meldola, Milan, Monza, Prato, Reggio Emilia
Age
18 years and over
People
660 worldwide
Run by
Genmab
See details and how to joinNCT07166094
Phase 1/2Taking people
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
Where
Rome
Age
18 years and over
People
160 worldwide
Run by
Eikon Therapeutics
See details and how to joinNCT07262619 · EU 2026-525248-13-00
Phase 3Taking people
A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting
Where
Bari, Bologna, Brescia, Florence, Lecco, Milan, Monza, Naples, Padova, Ponderano, Reggio Emilia, Rome, Turin
Age
18 years and over
People
710 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT07022483 · EU 2024-519444-33-00
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Bergamo, Genova, Naples, Verona
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
Phase 1/2Taking people
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Where
Candiolo, Milan, Naples, Rome, Rozzano
Age
18 years and over
People
680 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00
Phase 2Taking people
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Where
Brescia, Florence, Lecco, Milan, Rome
Age
18 years and over
People
393 worldwide
Run by
Canadian Cancer Trials Group
See details and how to joinNCT05640999
Phase 1/2Taking people
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Where
Milan, Modena, Roma
Age
18 years and over
People
460 worldwide
Run by
AstraZeneca
See details and how to joinNCT05123482 · EU 2022-502759-70-01
Phase 3Taking people
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Where
Catania, Florence, Milan, Monza, Naples, Reggio Emilia, Rome, Turin
Age
18 years and over
People
600 worldwide
Run by
AstraZeneca
See details and how to joinNCT06989112 · EU 2023-508056-19-00
Phase 3Taking people
Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features
Where
Rome
Age
18 years and over
People
316 worldwide
Run by
Leiden University Medical Center
See details and how to joinNCT05255653 · EU 2023-503267-42-00
Phase 1/2Taking people
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Where
Candiolo, Milan, Naples, Rome, Rozzano
Age
12 years and over
People
300 worldwide
Run by
PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750
Phase 1/2Taking people
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Where
Milan, Naples, Rome
Age
18 years and over
People
890 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT03564340 · EU 2024-510783-23-00
Phase 2Taking people
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Where
Milan, Naples
Age
18 years to 130 years
People
454 worldwide
Run by
AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00
Phase 1/2Taking people
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Where
Ancona, Aviano, Meldola, Milan, Naples, Orbassano, Ravenna, Verona
Age
18 years and over
People
534 worldwide
Run by
Revolution Medicines, Inc.
See details and how to joinNCT06128551
Phase 1Taking people
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Where
Candiolo, Rozzano
Age
18 years and over
People
540 worldwide
Run by
SystImmune Inc.
See details and how to joinNCT05983432
Phase 1/2Taking people
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Where
Milan
Age
18 years and over
People
47 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07213609
Phase 3Taking people
Sentinel Node Biopsy in Endometrial Cancer
Where
Udine
Age
18 years and over
People
760 worldwide
Run by
Queensland Centre for Gynaecological Cancer
See details and how to joinNCT04073706
No phaseTaking people
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Where
Meldola, Reggio Emilia, Roma
Age
18 years and over
People
2,285 worldwide
Run by
Guardant Health, Inc.
See details and how to joinNCT05059444
Phase 2Taking people
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Where
Aviano, Bologna, Catania, Milan, Naples, Rome, Turin
Age
18 years and over
People
350 worldwide
Run by
Acrivon Therapeutics
See details and how to joinNCT05548296 · EU 2025-524542-10-00
Phase 1/2Taking people
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Where
Bologna, Milan, Rome, Rozzano
Age
18 years and over
People
300 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04104776 · EU 2023-508002-20-00
Phase 3Taking people
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Endometrial Cancer ( RAINFOL-03 )
Where
Bari, Bologna, Brescia, Catania, Meldola, Milan, Monza, Naples, Pisa, Prato, Reggio Emilia, Rome, Turin
Age
18 years and over
People
290 worldwide
Run by
Genmab A/S
See details and how to join2024-519818-31-01 · EU 2024-519818-31-01